IL6 and early-onset autosomal dominant Alzheimer disease: Resveratrol has been recently tested showing significant clinical efficacy in combination with donepezil hydrochloride in Alzheimer’s disease patients by improving their inflammatory parameters, such as TNF-alpha and interleukine-6, as well as cognitive function estimated by mini-mental state examination and Alzheimer’s disease assessment scale cognitive subscale and prognosis (ADAS-Cog) during 2 months of treatment (Table 2) [48].